Tempus AI shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.

Dan Ives' AI Revolution ETF (IVES) is heavily weighted toward big tech, betting these giants will lead the AI boom. Click ...

Caris Life Sciences is now considered extended and out of buy range after clearing a 30.70 buy point in a first-stage ipo base. See if the stock forms a new pattern or follow-on buying opportunity ...

Tradr ETFs, a provider of ETFs designed for sophisticated investors and professional traders, announced today that it expects to launch two first-to-market leveraged single-stock ETFs on MongoDB ...